ATE206716T1 - Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität - Google Patents

Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität

Info

Publication number
ATE206716T1
ATE206716T1 AT96911444T AT96911444T ATE206716T1 AT E206716 T1 ATE206716 T1 AT E206716T1 AT 96911444 T AT96911444 T AT 96911444T AT 96911444 T AT96911444 T AT 96911444T AT E206716 T1 ATE206716 T1 AT E206716T1
Authority
AT
Austria
Prior art keywords
cyclic
cell membrane
membrane permeability
peptides
peptide
Prior art date
Application number
AT96911444T
Other languages
English (en)
Inventor
Donald T Borchardt
Teruna Siahaan
Sanjeev Gangwar
Valentino J Stella
Binghe Wang
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas filed Critical Univ Kansas
Application granted granted Critical
Publication of ATE206716T1 publication Critical patent/ATE206716T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96911444T 1995-04-25 1996-04-08 Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität ATE206716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/429,732 US5672584A (en) 1995-04-25 1995-04-25 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
PCT/US1996/004180 WO1997039024A1 (en) 1995-04-25 1996-04-08 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability

Publications (1)

Publication Number Publication Date
ATE206716T1 true ATE206716T1 (de) 2001-10-15

Family

ID=23704505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96911444T ATE206716T1 (de) 1995-04-25 1996-04-08 Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität

Country Status (9)

Country Link
US (1) US5672584A (de)
EP (1) EP0830372B1 (de)
JP (1) JPH11508275A (de)
AT (1) ATE206716T1 (de)
AU (1) AU702993B2 (de)
CA (1) CA2219151A1 (de)
DE (1) DE69615838T2 (de)
ES (1) ES2165492T3 (de)
WO (1) WO1997039024A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521737B1 (en) * 1995-11-10 2003-02-18 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
IE80466B1 (en) * 1995-11-10 1998-07-29 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP4465109B2 (ja) 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
EP2286792A1 (de) 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Mikroemulsionen mit einer adsorbierenden Oberfläche, enthaltend eine Mikrotropfenemulsion
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
DE19942624A1 (de) * 1999-08-28 2001-03-08 Chemotopix Gmbh Verfahren zur Herstellung von zyklischen Peptidomimetika
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
MXPA03007392A (es) * 2001-02-20 2003-12-04 Enzon Inc Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos.
WO2002087500A2 (en) * 2001-04-27 2002-11-07 Newbiotics, Inc. Viral enzyme activated prototoxophores and use of same to treat viral infections
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011566A (es) * 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
SI2332582T1 (sl) 2002-06-19 2014-03-31 Apeiron Biologics Ag Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije
WO2005044839A2 (en) * 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2005047245A2 (en) * 2003-11-14 2005-05-26 Wisconsin Alumni Research Foundation Fluorescence assays with improved blocking groups
EP1811986B1 (de) 2004-11-04 2014-03-26 XenoPort, Inc. Orale darreichungsformen von gabapentin-prodrug mit verzögerter freisetzung
EP1910379B1 (de) * 2005-07-28 2011-10-19 Vertex Pharmaceuticals Incorporated Caspase-hemmer-propharmaka
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
US7531572B2 (en) * 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
PL2118123T3 (pl) * 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
AU2008225100A1 (en) * 2007-03-12 2008-09-18 Mayo Foundation For Medical Education And Research Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
CN104961795A (zh) 2008-09-22 2015-10-07 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
EP2768518A4 (de) 2011-10-18 2015-05-27 Aileron Therapeutics Inc Peptidomimetische makrozyklen
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3197478A4 (de) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
CA3056681A1 (en) * 2017-03-23 2018-09-27 Trucode Gene Repair, Inc. Peptide nucleic acid (pna) monomers with an orthogonally protected ester moiety
US20200255492A1 (en) 2017-08-31 2020-08-13 University Of Dundee Leptin peptides and their use for treating neurological disorders
CN118184532A (zh) * 2018-12-12 2024-06-14 中外制药株式会社 具有能形成分子内氢键的官能团的氨基酸、包含该氨基酸的肽化合物、及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof

Also Published As

Publication number Publication date
AU5433096A (en) 1997-11-07
EP0830372B1 (de) 2001-10-10
CA2219151A1 (en) 1997-10-23
ES2165492T3 (es) 2002-03-16
JPH11508275A (ja) 1999-07-21
EP0830372A1 (de) 1998-03-25
WO1997039024A1 (en) 1997-10-23
AU702993B2 (en) 1999-03-11
US5672584A (en) 1997-09-30
DE69615838T2 (de) 2002-04-25
DE69615838D1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
DE69615838D1 (de) Cyclische wirkstoff-vorläufer verbindungen von peptiden und peptid-nukleicsäuren mit verbesserter metabolischer stabilität und zellmembran permeabilität
ATE259828T1 (de) Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
AU6819294A (en) Oral drug delivery compositions and methods
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
DK366889D0 (da) Peptidderivat
RU94033520A (ru) Впрыскиваемый лецитиновый гель
RU95108590A (ru) Производные имидазола
ATE295346T1 (de) N-(aryl/heteroarylacetyl)aminosäureester, diese enthaltende pharmazeutische zusammensetzungen und methoden zur inhibierung der beta- amyloidfreisetzung und/oder deren synthese unter verwendung dieser verbindungen
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
EA199900751A1 (ru) Фармацевтическая композиция, содержащая лиофилизированные липосомы, включающие инкапсулированный активный ингредиент, практически нерастворимый в воде, и способ получения композиции
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
ES2058479T3 (es) Compuestos peptidicos.
TR199902575T2 (xx) Peptitler, proteinler ve nükleik asitler için stabil farmasötik uygulama formu.
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
RU2004104335A (ru) Биологически активные пептиды
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
WO1999064439A3 (en) Methods for increasing cationic antimicrobial peptides
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
EP1007647A4 (de) Produktion des proteins ingap mit hoher expressionsrate
SE9904132D0 (sv) Pharmaceutical composition for treatment of diarrhea

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties